Chronic News and Research

RSS

Kylin receives $250,000 IRS award to advance pRNAi nanoparticle cancer treatment research

Officials of Kylin Therapeutics Inc. announces that they received a therapeutic discovery project grant from the U.S. Internal Revenue Service that will advance the company's pRNAi nanoparticle cancer treatment research.

11 Nov 2010

Experts call for global agriculture reform to ensure food security as two rice conferences open

Experts attending the International Rice Congress in Hanoi, Vietnam, on Tuesday called for imminent action to change inefficient farming methods and expand the global rice supply in order to prevent rising poverty and hunger, Agence France-Presse reports.

11 Nov 2010

Nplate reduces treatment failure and splenectomies in adults with chronic immune thrombocytopenia

Amgen Inc. today announced the publication of results from the first open-label study to compare Nplate® (romiplostim) treatment to standard of care therapies (SOC) in non-splenectomized adult patients with chronic immune thrombocytopenia (ITP). The study results, which were published today in the New England Journal of Medicine (NEJM), show that both the incidence of treatment failure and need for splenectomy were reduced among the Nplate-treated patients.

11 Nov 2010

Depression associated with molecular-level disturbance in body's 24-hour clock

Depression appears to be associated with a molecular-level disturbance in the body's 24-hour clock, new research suggests.

11 Nov 2010

Nutech Mediworld founder presents clinical study results of hESC therapy in patients with spinal cord injury

Dr. Geeta Shroff, founder & medical director of Nutech Mediworld, presented today the summary results of a retrospective clinical study of human embryonic stem cell (hESC) therapy in patients with chronic spinal cord injury (SCI).

11 Nov 2010

Antigen Express awarded Therapeutic Discovery Project grants for cancer vaccine development

Generex Biotechnology Corporationannounced today that its wholly-owned immunotherapeutics subsidiary, Antigen Express, Inc. has been awarded two Therapeutic Discovery Project grants, totaling $488,958.50, by the United States Internal Revenue Service (IRS) and the Department of Health and Human Services (HHS) pursuant to the Patient Protection and Affordable Care Act of 2010.

10 Nov 2010

CDC report: 50 million Americans uninsured

KBOI (Boise, Idaho)/ABC News Radio: "According to a new report by the Centers for Disease Control and Prevention, 49.9 million people ages 18 to 64," or about 26.2 percent of the adult population, "had no medical coverage for at least part of the past 12 months. … Moreover, when children 17 and under are factored in, the number of Americans uninsured for at least part of a year span numbered 59.1 million."

10 Nov 2010

Lung cancer in smokers versus non-smokers shows different genetic mutations

A group of scientists at B.C. Cancer Agency have found that lung cancers in smokers have different genetic mutations and look different than lung cancer in non-smokers. According to senior scientist at the BC Cancer Agency Research Centre Wan Lam, this finding is significant because it means that from now on, research, treatments and diagnostics should be tailored to the distinct genetic variations in the different lung cancers instead of expecting that a one-size fits all approach will work. He said, “At the current time, treatment does not distinguish between these different types. The subtypes are all grouped together. But with this work, we are beginning to tease out the subtypes.” The study was presented Tuesday at a conference in Philadelphia of the American Association of Cancer Research.

10 Nov 2010

Hemispherx Biopharma awarded grant for Ampligen, Alferon development programs

Hemispherx Biopharma, Inc. announced today grant awards totaling $488,958 from the U.S. Department of Treasury in support of its Ampligen and Alferon development programs.

10 Nov 2010

Zalicus third quarter total revenue decreases to $1.2 million

"We made solid product development progress this quarter," commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. "We finalized our development plans for Synavive, and also related to Synavive, we were awarded a Therapeutic Discovery Project grant to help fund Synavive development going forward.

10 Nov 2010

Abbott presents results of 2 pivotal HUMIRA studies at American College of Rheumatology meeting

Today, Abbott presents results from a pooled analysis of two pivotal HUMIRA® (adalimumab) studies, which look at patients with early and long-standing moderate to severe rheumatoid arthritis (RA), at the American College of Rheumatology meeting in Atlanta.

10 Nov 2010

Covidien analysis finds lower incidence of GI adverse events with topical NSAIDs versus oral

Covidien, a leading global provider of healthcare products, announced the results of an analysis that will be presented at the American College of Rheumatology's Annual Scientific Meeting. A pooled analysis of safety data suggests that patients with knee osteoarthritis (OA) receiving the topical PENNSAID® (diclofenac sodium topical solution) 1.5% w/w had significantly fewer gastrointestinal (GI)-related adverse events than those receiving an oral non-steroidal anti-inflammatory drug (NSAID).

10 Nov 2010

TRU-016 abstracts to be presented at ASH meeting

Emergent BioSolutions Inc. today announced the acceptance of four abstracts for presentation at the 52nd Annual Meeting of the American Society of Hematology to be held from December 4 to 7 in Orlando, Florida. The presentations include an oral presentation on the results of a Phase I dose escalation, monotherapy study of TRU-016 for patients with chronic lymphocytic leukemia.

10 Nov 2010

Psychologists find stress is taking physical and emotional health toll on family and children

Findings from the American Psychological Association's (APA) newly released 2010 Stress in America survey raise red flags about the long-term impact that chronic stress could have on our physical and emotional health and the health of our families, psychologists said today.

10 Nov 2010

NHLBI launches new campaign to highlight common COPD symptoms

The number of Americans who report being aware of chronic obstructive pulmonary disease, or COPD, increased by 4 percentage points between 2008 and 2010, but many people at risk are still unaware of the disease, according to mailed survey results released today by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.

10 Nov 2010

UC Davis researchers identify new pathway to repair oxidative-damaged DNA

UC Davis researchers have found a new pathway for repairing DNA damaged by oxygen radicals. The results are published this week in the journal Proceedings of the National Academy of Sciences.

10 Nov 2010

L. reuteri Prodentis effective for treating chronic periodontitis

The study shows that L. reuteri Prodentis acts synergistically with standard treatment (scaling and root plaining, SRP) to significantly reduce probing pocket depth (PPD) and clinical attachment level (CAL) which are the two most important parameters to assess the severity of periodontitis. Furthermore L. reuteri Prodentis reveals - as the first probiotic ever - significant reductions of three different pathogens in patients with chronic periodontitis.

10 Nov 2010

Education can help prevent preterm birth

Doctors and patients should discuss a pregnant woman's risk of preterm birth by the twelfth week of pregnancy, according to a commentary published in the November issue of Ob.Gyn. News.

10 Nov 2010

Iris BioTechnologies awarded $245,000 grant under QTDP Program

Iris BioTechnologies Inc., a life sciences company focused on providing patients, doctors, and clinicians with improved methods of identifying effective treatment solutions, and recipient of the Frost and Sullivan 2008 Technology Innovation Award in Pharmacogenomics, is pleased to announce that the company has been awarded $245,000, the maximum amount given for a grant under the US Qualifying Therapeutic Discovery Project (QTDP) Program.

10 Nov 2010

Emergent BioSolutions awarded five grants totalling $1.2 million under QTDP Program

Emergent BioSolutions Inc. today announced that it has been awarded five separate grants under the Qualifying Therapeutic Discovery Project (QTDP) Program to support continued development of its therapeutic programs in oncology and autoimmunity. The grants, with a total value of over $1.2 million, will fund Emergent's TRU-016 Small Modular ImmunoPharmaceutical (SMIP™), DRACO anti-CD3 SMIP, X1 TNF-based SCORPION™, X2 CTLA4-based SCORPION, and T-Scorps-based SCORPION therapeutic programs.

10 Nov 2010

Chronic News and Research

Kylin receives $250,000 IRS award to advance pRNAi nanoparticle cancer treatment research

Experts call for global agriculture reform to ensure food security as two rice conferences open

Nplate reduces treatment failure and splenectomies in adults with chronic immune thrombocytopenia

Depression associated with molecular-level disturbance in body's 24-hour clock

Nutech Mediworld founder presents clinical study results of hESC therapy in patients with spinal cord injury

Antigen Express awarded Therapeutic Discovery Project grants for cancer vaccine development

CDC report: 50 million Americans uninsured

Lung cancer in smokers versus non-smokers shows different genetic mutations

Hemispherx Biopharma awarded grant for Ampligen, Alferon development programs

Zalicus third quarter total revenue decreases to $1.2 million

Abbott presents results of 2 pivotal HUMIRA studies at American College of Rheumatology meeting

Covidien analysis finds lower incidence of GI adverse events with topical NSAIDs versus oral

TRU-016 abstracts to be presented at ASH meeting

Psychologists find stress is taking physical and emotional health toll on family and children

NHLBI launches new campaign to highlight common COPD symptoms

UC Davis researchers identify new pathway to repair oxidative-damaged DNA

L. reuteri Prodentis effective for treating chronic periodontitis

Education can help prevent preterm birth

Iris BioTechnologies awarded $245,000 grant under QTDP Program

Emergent BioSolutions awarded five grants totalling $1.2 million under QTDP Program

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News